Richard Toselli - CochLear Chief Medical Officer
| CHEOY Stock | USD 103.45 1.34 1.28% |
Executive
Dr. Richard Toselli was appointed as Chief Medical Officer of the Company. Rich will lead the Global Clinical, Regulatory and Health Economics teams to bring more strategic global coordination and integration. His focus will be on bringing stronger voice of customer to the product development process and sharpening the value proposition on our products by creating high quality clinical and health economic data. Rich joins Cochlear from Sanofi Genzyme Biologics Division where he was Head of Global Medical Affairs for Immunology. Rich trained as a neurosurgeon and has more than 12 years of experience in RD, Medical Affairs and Evidence Based Medicine. He previously held senior roles with Sanofi, Covidien and Johnson Johnson. since 2016.
| Tenure | 8 years |
| Phone | 61 2 9428 6555 |
| Web | https://www.cochlear.com |
CochLear Management Efficiency
The company has return on total asset (ROA) of 0.0973 % which means that it generated a profit of $0.0973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1713 %, meaning that it generated $0.1713 on every $100 dollars invested by stockholders. CochLear's management efficiency ratios could be used to measure how well CochLear manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Rebecca Markovich | Talis Biomedical Corp | 50 | |
| Bryan Olin | LivaNova PLC | 57 | |
| Christopher Lewis | Glaukos Corp | N/A | |
| John Harris | Integer Holdings Corp | 64 | |
| Jon Gingrich | Axogen Inc | 48 | |
| Hans Kestler | Paragon 28 | N/A | |
| Daniel Esq | CONMED | 60 | |
| Matt Brinckman | Paragon 28 | N/A | |
| Douglas Manko | LivaNova PLC | 44 | |
| Jeff Sears | Paragon 28 | N/A | |
| Eric Sandberg | Axogen Inc | N/A | |
| Tram Bui | Orthopediatrics Corp | N/A | |
| Robert JD | Paragon 28 | 56 | |
| Doris Quackenbush | Axogen Inc | N/A | |
| Harold Tamayo | Axogen Inc | N/A | |
| Brent Lalomia | CONMED | 49 | |
| Mark Ploof | Medtronic PLC | N/A | |
| Michael Donovan | Axogen Inc | 59 | |
| Jane Rady | Glaukos Corp | 76 | |
| Andrew Hill | Paragon 28 | 40 | |
| Mark Karshner | Orthopediatrics Corp | N/A | |
Management Performance
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0973 |
CochLear ADR Leadership Team
Elected by the shareholders, the CochLear's board of directors comprises two types of representatives: CochLear inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CochLear. The board's role is to monitor CochLear's management team and ensure that shareholders' interests are well served. CochLear's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CochLear's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Glen Boreham, Non-Executive Independent Director | ||
| Greg Bodkin, Senior Vice President - Supply Chain & Operational Excellence | ||
| Jan Janssen, Senior Vice President - Design and Development | ||
| Yasmin Allen, Non-Executive Director | ||
| Rom Mendel, President Acoustics | ||
| Jennifer Stevenson, VP Brand | ||
| Kristina Devon, VP Relations | ||
| Piers Shervington, Senior Corporate Communications Manager, Investor Relations Contact Officer | ||
| Lisa Aubert, Pres America | ||
| Christopher Smith, President - Americas Region | ||
| Katharine McLennan, Senior Vice President - People and Culture | ||
| Rick HollidaySmith, Non-Executive Chairman of the Board | ||
| Anthony Bishop, President - Asia Pacific | ||
| Dig Howitt, COO | ||
| Alison Deans, Non-Executive Independent Director | ||
| Brent Cubis, CFO | ||
| Donal ODwyer, Non-Executive Director | ||
| Edward Byrne, Non-Executive Director | ||
| Richard Toselli, Chief Medical Officer | ||
| Stuart Sayers, President - Services | ||
| Neville Mitchell, CFO, Company Secretary | ||
| Richard Brook, President - European Region | ||
| Dean Phizacklea, Senior Vice President Global Marketing | ||
| Amanda Lampe, Senior Vice President - Corporate Affairs, Strategic Alignment & Public Health | ||
| Jennifer Hornery, Senior Vice President - People & Culture | ||
| Richard MBA, Pres EMEA | ||
| Jan Eng, Chief Officer | ||
| Ray Jarman, Company Secretary | ||
| Andrew Denver, Non-Executive Director | ||
| Shah Hussain, Non-Executive Independent Director | ||
| Tony Manna, President Americas Region | ||
| David Hackshall, Chief Officer | ||
| MBA BE, MD, CEO | ||
| Diggory Howitt, President Executive Director | ||
| Bruce Robinson, Independent Non-Executive Director | ||
| David Cade, Chief Medical Officer |
CochLear Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CochLear a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0973 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 9.05 B | |||
| Shares Outstanding | 131.56 M | |||
| Price To Earning | 49.26 X | |||
| Price To Book | 8.15 X | |||
| Price To Sales | 5.55 X | |||
| Revenue | 1.65 B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CochLear in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CochLear's short interest history, or implied volatility extrapolated from CochLear options trading.
Pair Trading with CochLear
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CochLear position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CochLear will appreciate offsetting losses from the drop in the long position's value.Moving together with CochLear Pink Sheet
| 0.8 | SYK | Stryker Earnings Call This Week | PairCorr |
| 0.65 | BSX | Boston Scientific Corp Buyout Trend | PairCorr |
| 0.7 | SEMHF | Siemens Healthineers | PairCorr |
The ability to find closely correlated positions to CochLear could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CochLear when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CochLear - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CochLear Ltd ADR to buy it.
The correlation of CochLear is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CochLear moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CochLear ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CochLear can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CochLear Ltd ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for CochLear Pink Sheet analysis
When running CochLear's price analysis, check to measure CochLear's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CochLear is operating at the current time. Most of CochLear's value examination focuses on studying past and present price action to predict the probability of CochLear's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CochLear's price. Additionally, you may evaluate how the addition of CochLear to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |